| Title |
Single dose oral nefopam for acute postoperative pain in adults
|
|---|---|
| Published in |
Cochrane database of systematic reviews, July 2009
|
| DOI | 10.1002/14651858.cd007442.pub2 |
| Pubmed ID | |
| Authors |
Manish Kakkar, Sheena Derry, R Andrew Moore, Henry J McQuay |
| Abstract |
Nefopam is a centrally-acting but non-opioid analgesic drug of the benzoxazocine chemical class, developed in the early 1970s. It is widely used, mainly in European countries, for the relief of moderate to severe pain as an alternative to opioid analgesic drugs, and used in rheumatic disease and other musculoskeletal disorders in the UK. This review sought to evaluate the efficacy and safety of oral nefopam in acute postoperative pain, using clinical studies of patients with established pain, and with outcomes measured primarily over 6 hours using standard methods. This type of study has been used for many decades to establish that drugs have analgesic properties. |
Twitter Demographics
The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 67 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 13% |
| Researcher | 8 | 12% |
| Student > Bachelor | 5 | 7% |
| Other | 4 | 6% |
| Student > Doctoral Student | 3 | 4% |
| Other | 9 | 13% |
| Unknown | 29 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 27% |
| Nursing and Health Professions | 8 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Psychology | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 1% |
| Other | 4 | 6% |
| Unknown | 30 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2023.
All research outputs
#13,725,838
of 23,983,331 outputs
Outputs from Cochrane database of systematic reviews
#10,354
of 12,820 outputs
Outputs of similar age
#92,881
of 113,322 outputs
Outputs of similar age from Cochrane database of systematic reviews
#60
of 74 outputs
Altmetric has tracked 23,983,331 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,820 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.8. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 113,322 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.